SR9011
![]() | |
| Identifiers | |
|---|---|
| |
| CAS Number | 1379686-29-9 |
| PubChem (CID) | 57394021 |
| ChemSpider | 28487552 |
| ChEMBL | CHEMBL1961797 |
| Chemical and physical data | |
| Formula | C23H31ClN4O3S |
| Molar mass | 479.03524 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.[1]
See also
References
- ↑ Solt LA; Wang Y; Banerjee S; Hughes T; Kojetin DJ; Lundasen T; Shin Y; Liu J; Cameron MD; Noel R; Yoo SH; Takahashi JS; Butler AA; Kamenecka TM; Burris TP (May 2012). "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature. 485 (7396): 62–8. doi:10.1038/nature11030. PMC 3343186
. PMID 22460951. Lay summary – Nature Magazine.
This article is issued from Wikipedia - version of the 6/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
